lactic acid has been researched along with epirubicin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Birnbaum, DT; Brannon-Peppas, L | 1 |
| Hou, ZQ; Wang, XM; Weng, J; Ye, SF; Zhang, QQ; Zhou, JY; Zhou, ZM | 1 |
| Wang, XM; Ye, SF; Zhang, QQ; Zhou, JY | 1 |
| Fu, HX; Ji, JS; Li, H; Song, JJ; Zhu, YL | 1 |
| Chang, J; Han, L; Kang, C; Liao, Z; Pu, P; Su, W; Wang, G; Wang, H; Wang, S; Wang, X | 1 |
| Kazem, A; Nafee, N; Nasr, M; Saad, H | 1 |
| Alam, MA; Iqbal, Z; Panda, AK; Singh, AT; Talegaonkar, S; Tariq, M | 1 |
| Chung, FF; Hii, LW; Ho, GF; Leong, CO; Malik, RA; Ng, CH; See, MH; Soo, JS; Taib, NA; Tan, BS; Tan, SH; Teh, YC; Teo, SH; Yip, CH | 1 |
| Cai, X; Chen, H; Jia, Y; Lv, F; Nan, W; Qin, J; Xie, LQ; Yang, W; Zhang, QQ | 1 |
| Di-Wen, S; Hao, L; Pan, GZ; Wang, P; Xue, QZ; Yuan, QZ; Zhang, J | 1 |
| Alam, MA; Panda, AK; Singh, AT; Talegaonkar, S; Tariq, M | 2 |
| Abnous, K; Alibolandi, M; Ramezani, M; Taghavi, S; Taghdisi, SM | 1 |
15 other study(ies) available for lactic acid and epirubicin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl.
Topics: Biodegradation, Environmental; Chromatography, Gel; Delayed-Action Preparations; Drug Carriers; Epirubicin; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Molecular Weight; Nanotechnology; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2003 |
[Treatment of hepatocellular carcinoma in mice with locally administered epirubicin-loaded poly(D, L)-lactic acid microspheres].
Topics: Animals; Antibiotics, Antineoplastic; Delayed-Action Preparations; Drug Carriers; Epirubicin; Injections, Intraperitoneal; Lactic Acid; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred Strains; Microspheres; Polyesters; Polymers | 2006 |
[Efficacy of intraperitoneally injected epirubicin-loaded poly (d, l)-lactic acid microspheres alone or combined with free epirubicin in treating hepatocellular carcinoma in mice].
Topics: Animals; Delayed-Action Preparations; Epirubicin; Infusions, Parenteral; Lactic Acid; Liver Neoplasms, Experimental; Male; Mice; Microspheres; Polyesters; Polymers | 2009 |
[Preparation and quality control of compound epirubicin hydrochloride-loaded polymeric nanoparticles of L-lactic-co-glycolic acid].
Topics: Drug Carriers; Epirubicin; Lactic Acid; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Technology, Pharmaceutical | 2011 |
Smart multifunctional core-shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Epirubicin; Gene Transfer Techniques; Glioblastoma; Green Fluorescent Proteins; Humans; Lactic Acid; Magnetite Nanoparticles; Nanospheres; Plasmids; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Spectroscopy, Fourier Transform Infrared; Stomach; Xenograft Model Antitumor Assays | 2012 |
Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cardiotoxicity; Cell Survival; Chitosan; Disease Models, Animal; Drug Delivery Systems; Epirubicin; Glutathione; Heart; Hep G2 Cells; Hepatocytes; Humans; Lactic Acid; Lipid Peroxidation; Liver; Liver Neoplasms; Mice; Nanoparticles; Neovascularization, Pathologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Superoxide Dismutase; Tocotrienols; Tumor Suppressor Protein p53 | 2014 |
Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Biological Availability; Biological Transport; Caco-2 Cells; Cell Survival; Drug Carriers; Drug Compounding; Endocytosis; Epirubicin; Humans; Ileum; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Particle Size; Peyer's Patches; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2015 |
Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Cyclophosphamide; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Embryonic Stem Cells; Epirubicin; Female; Fibroblasts; Fluorouracil; Glucose; Humans; Hypoglycemic Agents; Lactic Acid; Lung; Metformin; Neoplastic Stem Cells; Pyrones; Ribonucleotides; Thiophenes | 2015 |
Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Topics: Animals; Antibiotics, Antineoplastic; Biotinylation; Breast Neoplasms; Carbocyanines; Cell Survival; Chitosan; Endocytosis; Epirubicin; Humans; Kinetics; Lactic Acid; MCF-7 Cells; Mice, Nude; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Photoelectron Spectroscopy; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Xenograft Model Antitumor Assays | 2016 |
Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers.
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Drug Liberation; Epirubicin; Hep G2 Cells; Humans; Lactic Acid; Liver Neoplasms; Mice; Microscopy, Electron, Transmission; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Treatment Outcome; Vitamin E | 2016 |
Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations.
Topics: Administration, Oral; Animals; Biological Availability; Biomarkers, Tumor; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Epirubicin; Lactic Acid; Mice; Mice, Inbred BALB C; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tissue Distribution | 2016 |
Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
Topics: Animals; Antibiotics, Antineoplastic; Biological Transport; Caco-2 Cells; Cell Survival; Drug Carriers; Drug Liberation; Epirubicin; Gastrointestinal Tract; Hexosamines; Humans; Ileum; Intestinal Absorption; Lactic Acid; MCF-7 Cells; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Wistar; Surface Properties | 2016 |
Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Topics: Adsorption; Animals; Antibiotics, Antineoplastic; Aptamers, Nucleotide; Cell Survival; Chitosan; CHO Cells; Colonic Neoplasms; Cricetulus; Drug Carriers; Drug Compounding; Drug Liberation; Epirubicin; Female; Humans; Lactic Acid; MCF-7 Cells; Mice, Inbred BALB C; Mucin-1; Nanomedicine; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Surface Properties; Technology, Pharmaceutical; Time Factors; Tumor Burden | 2017 |